Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 randomized placebo-controlled study of dupilumab on esophageal function and remodeling in adults with eosinophilic esophagitis
MOH_2023-06-12_012735Phase 4Recruiting
- Sponsor
- Sanofi
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Dupixent weekly with Placebo weekly then open-label Dupixent (2 arms). Primary endpoint: Change in esophageal distensibility at Week 24. Started Jul 2023; status: recruiting.
02
Drugs
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on MOH_2023-06-12_012735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-12_012735.